UCB, a global biopharmaceutical company, has signed a definitive agreement to acquire Candid Therapeutics, a privately held clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers (TCEs). Under the terms of the agreement, UCB will pay $2 billion upfront payments and up to $200 million in potential future milestone payments. The transaction is expected to close by the end of Q2 or early Q3 2026. This transaction sup...